{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:01:19Z","timestamp":1760101279191,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011338","name":"AstraZeneca Schweiz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00262-020-02757-8","type":"journal-article","created":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T10:02:30Z","timestamp":1604224950000},"page":"1255-1262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["SAKK 19\/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2"],"prefix":"10.1007","volume":"70","author":[{"name":"for the Swiss Group for Clinical Cancer Research (SAKK)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4090-7534","authenticated-orcid":false,"given":"Michael","family":"Mark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Froesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Innocents","family":"Eboulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miklos","family":"Pless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sacha I.","family":"Rothschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Dieter","family":"Janthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Burmeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Friedlaender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannis","family":"Metaxas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Wannesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schwitter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Baudoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Weindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Biaggi-Rudolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fr\u00fch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,1]]},"reference":[{"key":"2757_CR1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.4049\/jimmunol.1003496","volume":"187","author":"AM Paterson","year":"2011","unstructured":"Paterson AM, Brown KE, Keir ME et al (2011) The programmed death-1 ligand 1: B7\u20131 pathway restrains diabetogenic effector T cells in vivo. J Immunol 187:1097\u20131105","journal-title":"J Immunol"},{"key":"2757_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1200\/JCO.2013.53.1228","volume":"32","author":"DH Johnson","year":"2014","unstructured":"Johnson DH, Schiller JH, Bunn JP (2014) Recent clinical advances in lung cancer management. J Clin Oncol 32:973\u2013982","journal-title":"J Clin Oncol"},{"key":"2757_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/jco.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37:537\u2013546. https:\/\/doi.org\/10.1200\/jco.18.00149","journal-title":"J Clin Oncol"},{"key":"2757_CR4","doi-asserted-by":"publisher","first-page":"v915","DOI":"10.1093\/annonc\/mdz293","volume":"30","author":"D Spigel","year":"2019","unstructured":"Spigel D, De Marinis F, Giaccone G et al (2019) IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1\u2013selected NSCLC. Ann Oncol 30:v915","journal-title":"Ann Oncol"},{"issue":"Suppl 11","key":"2757_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1053\/j.seminoncol.2004.10.006","volume":"31","author":"R Govindan","year":"2004","unstructured":"Govindan R, Garfield DH (2004) Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol 31(Suppl 11):27\u201331. https:\/\/doi.org\/10.1053\/j.seminoncol.2004.10.006","journal-title":"Semin Oncol"},{"key":"2757_CR6","doi-asserted-by":"publisher","first-page":"iv123","DOI":"10.1093\/annonc\/mdi921","volume":"16","author":"V Gebbia","year":"2005","unstructured":"Gebbia V, Galetta D, De Marinis F (2005) Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials. Ann Oncol 16:iv123\u2013iv131","journal-title":"Ann Oncol"},{"key":"2757_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/annonc\/mdy474","volume":"30","author":"D Planchard","year":"2019","unstructured":"Planchard D, Popat S, Kerr K et al (2019) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:863\u2013870","journal-title":"Ann Oncol"},{"key":"2757_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1200\/jco.2010.28.18_suppl.2","volume":"28","author":"E Quoix","year":"2010","unstructured":"Quoix E, Oster J, Westeel V et al (2010) Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 28:2","journal-title":"J Clin Oncol"},{"key":"2757_CR9","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/jco.2012.48.1911","volume":"31","author":"M Zukin","year":"2013","unstructured":"Zukin M, Barrios CH, Pereira JR et al (2013) Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group Performance Status of 2. J Clin Oncol 31:2849\u20132853. https:\/\/doi.org\/10.1200\/jco.2012.48.1911","journal-title":"J Clin Oncol"},{"key":"2757_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","volume":"3","author":"RC Lilenbaum","year":"2008","unstructured":"Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D (2008) Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 3:125\u2013129. https:\/\/doi.org\/10.1097\/JTO.0b013e3181622c17","journal-title":"J Thorac Oncol"},{"issue":"15","key":"2757_CR11","doi-asserted-by":"publisher","first-page":"8032","DOI":"10.1200\/jco.2015.33.15_suppl.8032","volume":"33","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Brahmer JR, Ou S-HI et al (2015) Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 33(15):8032. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.8032","journal-title":"J Clin Oncol"},{"key":"2757_CR12","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart R, Morrow M, Hammond SA et al (2015) Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res 3:1052\u20131062","journal-title":"Cancer Immunol Res"},{"key":"2757_CR13","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.jtho.2019.06.010","volume":"14","author":"SJ Antonia","year":"2019","unstructured":"Antonia SJ, Balmanoukian A, Brahmer J et al (2019) Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC. J Thorac Oncol 14:1794\u20131806","journal-title":"J Thorac Oncol"},{"key":"2757_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cllc.2015.04.008","volume":"16","author":"F De Marinis","year":"2015","unstructured":"De Marinis F, Bria E, Baas P, Tiseo M, Camerini A, Favaretto AG, Gridelli C (2015) Treatment of unfit patients with advanced non-small-cell lung cancer: definition criteria according an expert panel. Clin Lung Cancer 16:399\u2013405. https:\/\/doi.org\/10.1016\/j.cllc.2015.04.008","journal-title":"Clin Lung Cancer"},{"key":"2757_CR15","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1200\/jco.18.02118","volume":"37","author":"A Passaro","year":"2019","unstructured":"Passaro A, Spitaleri G, Gyawali B, Marinis Fd (2019) Immunotherapy in non-small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence. J Clin Oncol 37:1863\u20131867. https:\/\/doi.org\/10.1200\/jco.18.02118","journal-title":"J Clin Oncol"},{"key":"2757_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013656","journal-title":"Am J Clin Oncol"},{"key":"2757_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11912-019-0852-9","volume":"21","author":"A Friedlaender","year":"2019","unstructured":"Friedlaender A, Banna GL, Buffoni L, Addeo A (2019) Poor-performance status assessment of patients with non-small cell lung cancer remains vague and blurred in the immunotherapy era. Curr Oncol Rep 21:107. https:\/\/doi.org\/10.1007\/s11912-019-0852-9","journal-title":"Curr Oncol Rep"},{"key":"2757_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.critrevonc.2018.06.016","volume":"129","author":"GL Banna","year":"2018","unstructured":"Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A, Cortinovis DL (2018) Immune-checkpoint inhibitors in non-small cell lung cancer: a tool to improve patients\u2019 selection. Crit Rev Oncol Hematol 129:27\u201339. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.06.016","journal-title":"Crit Rev Oncol Hematol"},{"key":"2757_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ctrc.2015.11.009","volume":"5","author":"A Malalasekera","year":"2016","unstructured":"Malalasekera A, Tan CSY, Phan V, Yip PY, Vardy J, Clarke S, Kao S (2016) Eastern Cooperative Oncology Group score: agreement between non-small-cell lung cancer patients and their oncologists and clinical implications. Cancer Treat Commun 5:17\u201321","journal-title":"Cancer Treat Commun"},{"issue":"15","key":"2757_CR20","doi-asserted-by":"publisher","first-page":"8103","DOI":"10.1200\/jco.2013.31.15_suppl.8103","volume":"31","author":"J Johansen","year":"2013","unstructured":"Johansen J, Boisen MK, Mellemgaard A, Holm B (2013) Prognostic value of ECOG performance status in lung cancer assessed by patients and physicians. J Clin Oncol 31(15):8103. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.8103","journal-title":"J Clin Oncol"},{"key":"2757_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","volume":"127","author":"E Felip","year":"2020","unstructured":"Felip E, Ardizzoni A, Ciuleanu T et al (2020) CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer 127:160\u2013172","journal-title":"Eur J Cancer"},{"key":"2757_CR22","doi-asserted-by":"publisher","first-page":"A1297O","DOI":"10.1093\/annonc\/mdx380.002","volume":"28","author":"D Spigel","year":"2017","unstructured":"Spigel D, McCleod M, Hussein M et al (2017) CheckMate 153: randomized results of continuous vs 1-year fixed-duration nivolumab in patients with advanced non-small-cell lung cancer. Ann Oncol 28:A1297O","journal-title":"Ann Oncol"},{"key":"2757_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.lungcan.2017.11.015","volume":"126","author":"E Dudnik","year":"2018","unstructured":"Dudnik E, Moskovitz M, Daher S et al (2018) Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data. Lung Cancer 126:217\u2013223","journal-title":"Lung Cancer"},{"key":"2757_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","volume":"145","author":"FG Dall\u2019Olio","year":"2020","unstructured":"Dall\u2019Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A (2020) ECOG performance status as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors; a systematic review and meta-analysis of real world data. Lung Cancer 145:95\u2013104. https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.027","journal-title":"Lung Cancer"},{"key":"2757_CR25","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/jgs.15750","volume":"67","author":"E Muchnik","year":"2019","unstructured":"Muchnik E, Loh KP, Strawderman M, Magnuson A, Mohile SG, Estrah V, Maggiore RJ (2019) Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer. J Am Geriatr Soc 67:905\u2013912. https:\/\/doi.org\/10.1111\/jgs.15750","journal-title":"J Am Geriatr Soc"},{"key":"2757_CR26","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.7150\/jca.31217","volume":"10","author":"H Katsura","year":"2019","unstructured":"Katsura H, Suga Y, Araya T, Kita T, Yoneda T, Tanaka N, Kawabata A, Ishita S, Mase H (2019) Efficacy and safety of nivolumab in patients with advanced non-small-cell lung cancer and poor performance status. J Cancer 10:2139","journal-title":"J Cancer"},{"key":"2757_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2020.02.023","volume":"130","author":"F Facchinetti","year":"2020","unstructured":"Facchinetti F, Mazzaschi G, Barbieri F et al (2020) First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer 130:155\u2013167. https:\/\/doi.org\/10.1016\/j.ejca.2020.02.023","journal-title":"Eur J Cancer"},{"issue":"9","key":"2757_CR28","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","volume":"8","author":"G Middleton","year":"2020","unstructured":"Middleton G, Brock K, Savage J et al (2020) Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med 8(9):895\u2013904. https:\/\/doi.org\/10.1016\/S2213-2600(20)30033-3","journal-title":"Lancet Respir Med"},{"key":"2757_CR29","doi-asserted-by":"publisher","first-page":"S2426","DOI":"10.1016\/j.jtho.2017.11.088","volume":"12","author":"R Juergens","year":"2017","unstructured":"Juergens R, Chu Q, Rothenstein J et al (2017) P2. 07\u2013029 CheckMate 169: safety\/efficacy of nivolumab in Canadian pretreated advanced NSCLC (including elderly and PS 2) patients. J Thorac Oncol 12:S2426\u2013S2427","journal-title":"J Thorac Oncol"},{"key":"2757_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2018.02.017","volume":"119","author":"D Fujimoto","year":"2018","unstructured":"Fujimoto D, Yoshioka H, Kataoka Y et al (2018) Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: a multicenter retrospective cohort study. Lung Cancer 119:14\u201320","journal-title":"Lung Cancer"},{"key":"2757_CR31","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jtho.2018.04.025","volume":"13","author":"MC Garassino","year":"2018","unstructured":"Garassino MC, Gelibter AJ, Grossi F et al (2018) Italian nivolumab expanded access program in nonsquamous non-small cell lung cancer patients: results in never-smokers and EGFR-mutant patients. J Thorac Oncol 13:1146\u20131155","journal-title":"J Thorac Oncol"},{"key":"2757_CR32","doi-asserted-by":"publisher","first-page":"v920","DOI":"10.1093\/annonc\/mdz394.082","volume":"30","author":"A Ardizzoni","year":"2019","unstructured":"Ardizzoni A, Azevedo S, Viquiera BR et al (2019) Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (NSCLC). Ann Oncol 30:v920\u2013v921","journal-title":"Ann Oncol"},{"key":"2757_CR33","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1002\/cncr.32782","volume":"126","author":"LA Petrillo","year":"2020","unstructured":"Petrillo LA, El-Jawahri A, Nipp RD, Lichtenstein MR, Durbin SM, Reynolds KL, Greer JA, Temel JS, Gainor JF (2020) Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors. Cancer 126:2288\u20132295","journal-title":"Cancer"},{"key":"2757_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1781249","author":"A Friedlaender","year":"2020","unstructured":"Friedlaender A, Metro G, Signorelli D et al (2020) Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score \u2265\u00a050% treated with front-line pembrolizumab. Acta Oncol. https:\/\/doi.org\/10.1080\/0284186X.2020.1781249","journal-title":"Acta Oncol"},{"key":"2757_CR35","doi-asserted-by":"crossref","unstructured":"Barlesi F (2019) Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: overall survival analysis of checkmate 817. WCLC 2019: Abstract OA04.02 and ESMO IO 2019","DOI":"10.1093\/annonc\/mdz451.001"},{"key":"2757_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB (2019) Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 7:306. https:\/\/doi.org\/10.1186\/s40425-019-0805-8","journal-title":"J Immunother Cancer"},{"key":"2757_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02613-9","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Tiseo M, Banna GL et al (2020) Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of \u2265 50%. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-020-02613-9","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02757-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T05:10:01Z","timestamp":1618636201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02757-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2757"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02757-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2020,11,1]]},"assertion":[{"value":"1 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Mark received advisory fees from BMS, MSD, AstraZeneca, Roche, and Takeda; and received institutional research grants from AstraZeneca. Dr. Froesch received advisory fees from Roche, Takeda, Pfizer, and Boehringer Ingelheim. Dr. Addeo received compensation from Bristol-Myers Squibb, AstraZeneca, Merck Sharpe & Dohme, Takeda, Pfizer, Roche, and Boehringer Ingelheim for participating in advisory boards. Dr. Fr\u00fch received advisory fees (paid to institution) from Bristol-Myers Squibb, Merck Sharpe & Dohme, AstraZeneca, Boehringer Ingelheim, Roche, and Takeda; and received institutional research grants from Bristol-Myers Squibb and AstraZeneca. Dr. Rothschild received honoraria (paid to institution) from Roche and AstraZeneca; and received consultancy\/advisory fees (paid to institution) from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Eisai, and Eli Lilly. Dr. Pless received compensation from Abbvie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eisai, Merck Sharpe & Dohme, Novartis, Pfizer, Roche, Takeda, and Merck for participating in advisory boards; received travel grants from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Roche, Takeda, and Vifor; and received speaking fees from Janssen. Dr. Weindler received honoraria (paid to institution) from Merck; and received travel grants (paid to institution) from Roche. The remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}